The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Medifast's revenues will grow 8.3% and EPS will grow 8.5%.
The average estimate for revenue is $101.3 million. On the bottom line, the average EPS estimate is $0.51.
Last quarter, Medifast notched revenue of $96.0 million. GAAP reported sales were 8.0% higher than the prior-year quarter's $88.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, EPS came in at $0.43. GAAP EPS of $0.43 for Q1 were 48% higher than the prior-year quarter's $0.29 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 75.4%, 30 basis points better than the prior-year quarter. Operating margin was 8.9%, 200 basis points better than the prior-year quarter. Net margin was 6.2%, 170 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $386.4 million. The average EPS estimate is $1.80.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 257 members out of 309 rating the stock outperform, and 52 members rating it underperform. Among 72 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give Medifast a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medifast is outperform, with an average price target of $31.90.
Looking for alternatives to Medifast? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Medifast to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Sunrun, Medifast, and Zumiez Slumped Today
Even though the market climbed, these stocks missed out. Find out why.
3 Stocks to Get on Your Watchlist
A cheap global automaker, a clinical-stage biopharmaceutical company with intriguing early-stage results, and a potentially overvalued weight-control company are this week's must-watch stocks.
Why Shares of Medifast Inc. Jumped
Is this meaningful? Or just another movement?